ALDX — Aldeyra Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Aldeyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -57.8 | -62 | -37.5 | -55.9 | -33.8 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.52 | 8.57 | 6.09 | 6.48 | 5.43 |
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 7.44 | -3.44 | 0.861 | 5.91 | -5.18 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -42.6 | -56.6 | -30.3 | -43.2 | -33.3 |
| Capital Expenditures | -0.008 | -0.016 | 0 | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -29.9 | 30 | -44.9 | 47.7 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.008 | -30 | 30 | -44.9 | 47.7 |
| Financing Cash Flow Items | 0.062 | 0.097 | -0.422 | 0.038 | 0.02 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 194 | 1.22 | -1.27 | -0.171 | 1.12 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 152 | -85.4 | -1.6 | -88.3 | 15.5 |